Literature DB >> 6140673

Characterization and localization of 3H-arginine8-vasopressin binding to rat kidney and brain tissue.

D M Dorsa, L A Majumdar, F M Petracca, D G Baskin, L E Cornett.   

Abstract

Anatomic, behavioral and pharmacologic evidence suggests that arginine8-vasopressin (AVP) serves as a CNS neurotransmitter or neuromodulator. We have characterized AVP binding to membrane and tissue slice preparations from brain and kidney, and examined the anatomical distribution of these binding sites. Conditions for the binding assay were optimized using kidney medullary tissue. Binding of 3H-AVP (S.A. = 30-51 Ci/mmol, NEN) to brain and kidney membranes and tissue slices was saturable, temperature dependent, linearly related to protein concentration (or number of tissue slices), reversible, and specific since the ability of cold AVP to displace 3H-AVP from binding was greater than oxytocin and other related peptide fragments. Autoradiographic localization of 3H-AVP binding was restricted to kidney medullary tissue. In brain tissue, 3H-AVP binding was found to occur in concentrated foci. Brainstem areas such as the nucleus tractus solitarius (NTS) showed a high density of AVP binding sites. Since local injections of AVP into the NTS have been shown to influence blood pressure, the present study presents the first anatomical evidence for the presence of AVP specific binding sites which might mediate this effect.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6140673     DOI: 10.1016/0196-9781(83)90021-9

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  10 in total

1.  Characterization of human platelet vasopressin receptors.

Authors:  M Thibonnier; J M Roberts
Journal:  J Clin Invest       Date:  1985-11       Impact factor: 14.808

Review 2.  Gut endocrine and neural peptides.

Authors:  Anne E Bishop; Julia M Polak
Journal:  Endocr Pathol       Date:  1990-03       Impact factor: 3.943

3.  Activation of multiple intracellular transduction signals by vasopressin in vasopressin-sensitive neurones of the rat supraoptic nucleus.

Authors:  N Sabatier; P Richard; G Dayanithi
Journal:  J Physiol       Date:  1998-12-15       Impact factor: 5.182

4.  Different localization and regulation of two types of vasopressin receptor messenger RNA in microdissected rat nephron segments using reverse transcription polymerase chain reaction.

Authors:  Y Terada; K Tomita; H Nonoguchi; T Yang; F Marumo
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

5.  Cardiovascular effects of injections of vasopressin into the nucleus tractus solitarius in conscious rats.

Authors:  K A King; C C Pang
Journal:  Br J Pharmacol       Date:  1987-03       Impact factor: 8.739

6.  Transmembrane domain IV of the Gallus gallus VT2 vasotocin receptor is essential for forming a heterodimer with the corticotrophin releasing hormone receptor.

Authors:  Marina V Mikhailova; Jonathan Blansett; Sandie Jacobi; Philip R Mayeux; Lawrence E Cornett
Journal:  J Biomed Opt       Date:  2008 May-Jun       Impact factor: 3.170

Review 7.  Vasopressin and oxytocin receptor systems in the brain: Sex differences and sex-specific regulation of social behavior.

Authors:  Kelly M Dumais; Alexa H Veenema
Journal:  Front Neuroendocrinol       Date:  2015-05-04       Impact factor: 8.606

8.  Pharmacological characterization of two specific binding sites for neurohypophyseal hormones in hippocampal synaptic plasma membranes of the rat.

Authors:  S Audigier; C Barberis
Journal:  EMBO J       Date:  1985-06       Impact factor: 11.598

9.  New insights into the transcriptional regulation of aquaporin-2 and the treatment of X-linked hereditary nephrogenic diabetes insipidus.

Authors:  Hyun Jun Jung; Tae-Hwan Kwon
Journal:  Kidney Res Clin Pract       Date:  2019-06-30

10.  A snake toxin as a theranostic agent for the type 2 vasopressin receptor.

Authors:  Laura Droctové; Manon Lancien; Vu Long Tran; Michaël Susset; Benoit Jego; Frederic Theodoro; Pascal Kessler; Gilles Mourier; Philippe Robin; Sékou Siramakan Diarra; Stefano Palea; Adrien Flahault; Amélia Chorfa; Maithé Corbani; Catherine Llorens-Cortes; Bernard Mouillac; Christiane Mendre; Alain Pruvost; Denis Servent; Charles Truillet; Nicolas Gilles
Journal:  Theranostics       Date:  2020-09-18       Impact factor: 11.556

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.